Determinants of Serum Sclerostin in Healthy Pre- and Postmenopausal Women
Determinants of Serum Sclerostin in Healthy Pre- and Postmenopausal Women
复制标题
DOI：
10.1002/jbmr.479
复制
发表时间：
2011-12-01
影响因子：
6.2
通讯作者：
Qari, Mohammed H.
中科院分区：
文献类型：
--
作者：
Ardawi, Mohammed-Salleh M.;Al-Kadi, Hanan A.;Qari, Mohammed H.
硬化蛋白是一种分泌型Wnt拮抗剂，几乎完全由骨细胞产生，调节骨量。然而，目前在一项基于大规模人群的研究中，关于sclerostin决定因素的信息有限。本研究的主要目的是：（1）建立随机选择的健康绝经前妇女血清sclerostin的参考标准区间值;（2）研究绝经前和绝经后妇女血清sclerostin与年龄的关系以及可能影响骨转换的因素;（3）确定绝经状态对血清sclerostin的影响。共研究了1803名女性（包括[n = 1235]名绝经前女性和[n = 5681名绝经后女性，年龄分别为20 - 79岁）。共有443名健康绝经前妇女（年龄35至45岁）被用来建立血清硬化素的参考标准区间。所有研究的女性都进行了医学检查，并根据详细的入选标准获得了腰椎（L-1-L-4）和股骨颈的骨密度值。在所有女性中，血清硬化素的值随着年龄的增加而增加，直到45岁，并且在绝经后女性中保持增加。绝经后妇女血清硬化素水平随绝经年限的增加而明显升高。使用逐步多元线性回归分析，确定了几个变量作为血清硬化素的决定因素，包括绝经前妇女的年龄、甲状旁腺激素、雌二醇（E-2）和促卵泡激素（FSH）;绝经后妇女的年龄、FSH和E-2;以及整个研究样本中的年龄、血清骨钙素、FSH和E-2。需要进一步的研究来确定这种增加在介导已知的与年龄相关的骨形成损伤中的潜在作用。(C)2011年美国骨与矿物质研究学会。
Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass. However, there is currently limited information on the determinants of sclerostin in a large population-based study. The main objectives of the present study were to: (1) establish reference normative interval values for serum sclerostin in randomly selected healthy premenopausal women; (2) study the changes in serum sclerostin in relation to age in premenopausal and postmenopausal women and the factors that may influence bone turnover; and (3) determine the effect of menopausal status on serum sclerostin. A total of 1803 women were studied (including [n = 1235] premenopausal, and [n = 5681 postmenopausal women, respectively, aged 20 to 79 years). A total of 443 healthy premenopausal women (aged 35 to 45 years) were used to establish reference normative intervals for serum sclerostin. All women studied were medically examined and had their bone mineral density values obtained for the lumbar spine (L-1-L-4) and femoral neck according to a detailed inclusion criteria. In all women, values of serum sclerostin increased with increasing age up to the age of 45 years, and remained increased in postmenopausal women. Significant increases were evident in serum sclerostin in postmenopausal women with increasing years since menopause. Using stepwise multiple linear regression analysis, several variables were identified as determinants of serum sclerostin, including age, parathyroid hormone, estradiol (E-2), and follicle-stimulating hormone (FSH) for premenopausal women; age, FSH, and E-2 for postmenopausal women; and age, serum osteocalcin, FSH, and E-2 in the entire sample studied. Further studies are needed to establish the potential role of this increase in mediating the known age-related impairment in bone formation. (C) 2011 American Society for Bone and Mineral Research.